Fortrea Holdings Inc. (FTRE)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Fortrea Holdings beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported October 29, 2026, with adjusted EPS of $0.28 topping the $0.22 estimate (+29%) and revenue of $691.5 million topping the $671.6 million estimate (+3%). On a year-over-year basis, revenue slipped 1.4% to about $691.5 million from roughly $701.3 million a year ago, while adjusted EPS rose 133.3% to $0.28 from $0.12. The company, which provides contract research services across its Clinical Services and Enabling Services segments, generated about $139.5 million of gross profit, translating to a gross margin of about 20.2%, and posted operating income of roughly $15.0 million for an operating margin near 2.2%. Cash generation in the quarter included operating cash flow of about $60.8 million. For the next period, consensus calls for EPS of $0.23 on revenue of $674.7 million.
About Fortrea Holdings Inc.
Fortrea Holdings Inc. provides contract research and related support to pharmaceutical companies, biotechnology clients, and medical device makers, helping them run clinical studies and related programs globally. The company, which trades on the NASDAQ as FTRE, generated $2.7 billion of revenue in FY2025.
Today's Snapshot
FTRE closed 7.9% below yesterday's close, while its sector was flat.
Trading Volume
Below 10d avg (1.6M)
1.5M
vs S&P 500 Today
Strong Underperformance
-4.45%
Updated: November 20, 2026 at 21:25 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$17.22 - $20.73Sell
- RSI (14)37.46Neutral
- Stochastic %K (14, 3, 3)22.66Neutral
- MACD Level (12, 26)-0.54Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.